AR086196A1 - Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa - Google Patents
Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasaInfo
- Publication number
- AR086196A1 AR086196A1 ARP120101360A AR086196A1 AR 086196 A1 AR086196 A1 AR 086196A1 AR P120101360 A ARP120101360 A AR P120101360A AR 086196 A1 AR086196 A1 AR 086196A1
- Authority
- AR
- Argentina
- Prior art keywords
- diseases
- alkylcycloalkyl
- heterocycloalkyl
- aralkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Compuestos de fórmula (1) capaces de inhibir una o más quinasas, especialmente SYK (tirosina quinasa esplénica), LRRK2 (quinasa con repeticiones ricas en leucina 2) y/o MYLK (quinasa de cadena ligera de miosina) o mutantes de estas. Los compuestos encuentran aplicación en el tratamiento de una variedad de enfermedades. Estas enfermedades incluyen enfermedades autoinmunes, enfermedades inflamatorias, enfermedades óseas, metabólicas, neurológicas y neurodegenerativas, cáncer, enfermedades cardiovasculares, alergias, asma, enfermedad de Alzheimer, enfermedad de Parkinson, trastornos de la piel, enfermedades del ojo, enfermedades infecciosas y enfermedades hormonales.Reivindicación 1: Un compuesto de fórmula (1) donde A es NH, O, S, C=O, NR3 o CR4R5; Cy es un grupo arilo, heteroarilo, cicloalquilo, heterocicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, aralquilo o heteroaralquilo opcionalmente sustituido; R1 es un grupo alquilo, alquenilo, alquinilo, heteroalquilo, arilo, heteroarilo, cicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, heterocicloalquilo, aralquilo o heteroaralquilo opcionalmente sustituido; R2 es un átomo de hidrógeno, un átomo de halógeno, NO2, N3, OH, SH, NH2 o un grupo alquilo, alquenilo, alquinilo, heteroalquilo, arilo, heteroarilo, cicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, heterocicloalquilo, aralquilo o heteroaralquilo; R3 es un grupo alquilo, alquenilo, alquinilo, heteroalquilo, arilo, heteroarilo, cicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, heterocicloalquilo, aralquilo o heteroaralquilo; R4 es un átomo de hidrógeno NO3, N3, OH, SH, NH2 o un grupo alquilo, alquenilo, alquinilo, heteroalquilo, arilo, heteroarilo, cicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, heterocicloalquilo, aralquilo o heteroaralquilo; y R5 es un átomo de hidrógeno NO3, N3, OH, SH, NH2 o un grupo alquilo, alquenilo, alquinilo, heteroalquilo, arilo, heteroarilo, cicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, heterocicloalquilo, aralquilo o heteroaralquilo; o una sal, un éster, un solvato o un hidrato farmacéuticamente aceptables del mismo o una formulación farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11003373 | 2011-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086196A1 true AR086196A1 (es) | 2013-11-27 |
Family
ID=44501589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101360 AR086196A1 (es) | 2011-04-21 | 2012-04-20 | Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR086196A1 (es) |
| UY (1) | UY34032A (es) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10407446B2 (en) | 2016-12-20 | 2019-09-10 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
| JP2020517711A (ja) * | 2017-04-27 | 2020-06-18 | バーディー バイオファーマシューティカルズ インコーポレイテッド | ２−アミノ−キノリン誘導体 |
| US11517567B2 (en) | 2017-06-23 | 2022-12-06 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
| US11633495B2 (en) | 2014-01-10 | 2023-04-25 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for immunotherapy |
| US11702476B2 (en) | 2016-01-07 | 2023-07-18 | Birdie Biopharmaceuticals, Inc. | Anti-EGFR combinations for treating tumors |
-
2012
- 2012-04-20 AR ARP120101360 patent/AR086196A1/es not_active Application Discontinuation
- 2012-04-20 UY UY34032A patent/UY34032A/es active IP Right Grant
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11633495B2 (en) | 2014-01-10 | 2023-04-25 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for immunotherapy |
| US11633494B2 (en) | 2014-01-10 | 2023-04-25 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for immunotherapy |
| US11786604B2 (en) | 2014-01-10 | 2023-10-17 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for treating HER2 positive tumors |
| US11702476B2 (en) | 2016-01-07 | 2023-07-18 | Birdie Biopharmaceuticals, Inc. | Anti-EGFR combinations for treating tumors |
| US10407446B2 (en) | 2016-12-20 | 2019-09-10 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
| US11136340B2 (en) | 2016-12-20 | 2021-10-05 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
| US11746118B2 (en) | 2016-12-20 | 2023-09-05 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
| JP2020517711A (ja) * | 2017-04-27 | 2020-06-18 | バーディー バイオファーマシューティカルズ インコーポレイテッド | ２−アミノ−キノリン誘導体 |
| US11834448B2 (en) | 2017-04-27 | 2023-12-05 | Birdie Biopharmaceuticals, Inc. | 2-amino-quinoline derivatives |
| US11517567B2 (en) | 2017-06-23 | 2022-12-06 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
| US12295950B2 (en) | 2017-06-23 | 2025-05-13 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| UY34032A (es) | 2012-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201301183A1 (ru) | Гетероциклические соединения в качестве ингибиторов киназ | |
| EA201301184A1 (ru) | Пиразоло[4,3-d]пиримидины, пригодные в качестве ингибиторов киназ | |
| EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
| MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| PH12016500359A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| EA201290807A1 (ru) | Циклобутановые и метилциклобутановые производные в качестве ингибиторов янус-киназы | |
| EA201390579A1 (ru) | Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы | |
| BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
| MX2012004089A (es) | Inhibidores de hsp90. | |
| EA201200318A1 (ru) | Гетероциклические оксимы | |
| MD4575B1 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| EA201600636A1 (ru) | 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды | |
| WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
| NZ599356A (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | |
| RU2012125971A (ru) | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных | |
| AR086196A1 (es) | Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa | |
| IN2014DN07885A (es) | ||
| NZ598144A (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy | |
| EA201791367A1 (ru) | Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы | |
| GB201302704D0 (en) | Therapeutic compounds | |
| CY1118552T1 (el) | Νεα παραγωγα πυριμιδινης ως αναστολεις φωσφοδιεστερασης 10 (pde-10) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |